Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL5214385

CC(C)c1ccc(NC(=O)CN(C(=O)c2cccc(CN)c2)c2ccccc2)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.46
RAB9A P51151 2/20 0.44
THRB P10828 1/20 0.42
KMT2A Q03164 2/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.40
ITGB1 P05556 1/20 0.40
ITGA4 P13612 1/20 0.40
TPSAB1 Q15661 4/20 0.39
NPC1 O15118 1/20 0.39
PLG P00747 2/20 0.39
KLK1 P06870 2/20 0.39
KLK6 Q92876 2/20 0.39
EPHX1 P07099 1/20 0.39
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL5210202 0.94 LMNA (0.39) LMNARAB9AKMT2AMAPTITGB1
Trifluoroacetic Acid SCHEMBL5243817 0.91 TPSAB1 (0.40) KMT2AMAPTMEN1ITGB1TPSAB1
Trifluoroacetic Acid SCHEMBL5212474 0.91 CFD (0.44) KMT2AMAPTMEN1TPSAB1
Trifluoroacetic Acid SCHEMBL5208605 0.90 KMT2A (0.47) RAB9AKMT2AMAPTMEN1POLB
SCHEMBL5210208 0.88 LMNA (0.37) LMNARAB9AKMT2AMAPTPOLB
Trifluoroacetic Acid SCHEMBL5210679 0.88 CFD (0.46) KMT2ATPSAB1
Trifluoroacetic Acid SCHEMBL5216743 0.86 TPSAB1 (0.39) KMT2AMAPTTPSAB1
Trifluoroacetic Acid SCHEMBL5247872 0.85 RAB9A (0.41) LMNARAB9AKMT2AMAPTTPSAB1
Trifluoroacetic Acid SCHEMBL8043425 0.85 CFD (0.46) KMT2ATPSAB1
Trifluoroacetic Acid SCHEMBL5244116 0.84 CFD (0.43) KMT2ATPSAB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1240154-B1 SERINE PROTEASE INHIBITORS TULARIK LTD (GB) 2007-02-28 EP disclosed
US-7157585-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2007-01-02 US disclosed
US-20050215587-A1 Serine protease inhibitors LIVELY SARAH E 2005-09-29 US disclosed
US-6916957-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2005-07-12 US disclosed
US-20030018059-A1 Serine protease inhibitors PROTHERICS MOLECULAR DESIGN LIMITED (GB) 2003-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215587-A1 Serine protease inhibitors PRSS1, TPSAB1, CMA1 LMNA 563/4885RAB9A 2685/4885THRB 2669/4885
US-20030018059-A1 Serine protease inhibitors TPSAB1, PRSS1, SERPINB1 LMNA 865/4885RAB9A 2314/4885THRB 3698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.